In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy
Authors
Keywords
-
Journal
Science Advances
Volume 8, Issue 3, Pages -
Publisher
American Association for the Advancement of Science (AAAS)
Online
2022-01-22
DOI
10.1126/sciadv.abj6901
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver
- (2021) M. Kim et al. Science Advances
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
- (2021) Julian D. Gillmore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
- (2021) Jeong Pil Han et al. Biology-Basel
- Hemophilia therapy: the future has begun
- (2020) Pier Mannuccio Mannucci HAEMATOLOGICA
- AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
- (2020) Helena Costa Verdera et al. MOLECULAR THERAPY
- Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing
- (2020) Qiang Cheng et al. Nature Nanotechnology
- Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver
- (2020) Lei Miao et al. Nature Communications
- Lipid nanoparticle technology for therapeutic gene regulation in the liver
- (2020) Dominik Witzigmann et al. ADVANCED DRUG DELIVERY REVIEWS
- Spectroscopic Evaluation of Red Blood Cells of Thalassemia Patients with Confocal Microscopy: A Pilot Study
- (2020) Laura Rey-Barroso et al. SENSORS
- Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing
- (2020) Muhammad Naeem et al. Cells
- CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future
- (2020) Fathema Uddin et al. Frontiers in Oncology
- Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
- (2019) Morgan L. Maeder et al. NATURE MEDICINE
- Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing
- (2019) Danny Wilbie et al. ACCOUNTS OF CHEMICAL RESEARCH
- Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A
- (2019) H. Marijke van den Berg et al. BLOOD
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results
- (2019) Amy D. Shapiro et al. BLOOD
- Hemophilia A and B: molecular and clinical similarities and differences
- (2019) Giancarlo Castaman et al. HAEMATOLOGICA
- Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
- (2019) Alireza Shahryari et al. Frontiers in Genetics
- The Development of Functional Non-Viral Vectors for Gene Delivery
- (2019) Patil et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Immunogenicity of Cas9 Protein
- (2019) Aditi Mehta et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Advances and innovations in haemophilia treatment
- (2018) Rob Peters et al. NATURE REVIEWS DRUG DISCOVERY
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
- (2018) David Adams et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing
- (2018) Jonathan D. Finn et al. Cell Reports
- Emerging Issues in AAV-Mediated In Vivo Gene Therapy
- (2018) Pasqualina Colella et al. Molecular Therapy-Methods & Clinical Development
- Directed evolution of CRISPR-Cas9 to increase its specificity
- (2018) Jungjoon K. Lee et al. Nature Communications
- Cas9 immunity creates challenges for CRISPR gene editing therapies
- (2018) Julie M. Crudele et al. Nature Communications
- Prevalence of and risk factors for cerebral microbleeds among adult patients with haemophilia A or B
- (2017) H. Husseinzadeh et al. HAEMOPHILIA
- Enhanced proofreading governs CRISPR–Cas9 targeting accuracy
- (2017) Janice S. Chen et al. NATURE
- Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
- (2017) Hao Yin et al. NATURE BIOTECHNOLOGY
- Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
- (2017) K. John Pasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adeno-Associated Virus Gene Therapy for Liver Disease
- (2016) Lisa M. Kattenhorn et al. HUMAN GENE THERAPY
- The past and future of haemophilia: diagnosis, treatments, and its complications
- (2016) Flora Peyvandi et al. LANCET
- In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs
- (2016) Yong Wu et al. Scientific Reports
- In vivo genome editing of the albumin locus as a platform for protein replacement therapy
- (2015) R. Sharma et al. BLOOD
- An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
- (2015) Alfica Sehgal et al. NATURE MEDICINE
- Digenome-seq: genome-wide profiling of CRISPR-Cas9 off-target effects in human cells
- (2015) Daesik Kim et al. NATURE METHODS
- Targeting Antithrombin to Treat Hemophilia
- (2015) Margaret V. Ragni NEW ENGLAND JOURNAL OF MEDICINE
- Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden
- (2013) S. Lövdahl et al. HAEMOPHILIA
- Endogenous factor VIII synthesis from the intron 22–inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A
- (2013) Gouri Shankar Pandey et al. NATURE MEDICINE
- Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer
- (2012) G. Buchlis et al. BLOOD
- Surgical Experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX
- (2011) L. A. VALENTINO et al. HAEMOPHILIA
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors
- (2010) Sylvie Boutin et al. HUMAN GENE THERAPY
- Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors
- (2009) Gary C. Pien et al. JOURNAL OF CLINICAL INVESTIGATION
- The Haemostatic Role of Tissue Factor Pathway Inhibitor
- (2007) James T.B. Crawley et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now